Long Island Biotech Company Wins Highest Award of Honor
In the International Biotechnology Industry
SAN DIEGO, June 26 /PRNewswire/ -- OSI Pharmaceuticals, Inc. was presented
with the 6th Annual Helix Award at the Biotechnology Industry Organization's
2001 International Biotechnology Convention and Exhibition held at the San
Diego Convention Center.
"We are delighted to receive this prestigious award and to be recognized
for our achievements in 2000," stated Colin Goddard, Ph.D., chairman and Chief
Executive Officer, OSI Pharmaceuticals. "It is particularly rewarding to have
our team of scientists and business professionals acknowledged for their
dedication towards advancing breakthrough therapies in cancer and other
serious diseases for patients around the world."
The award was presented at the luncheon ceremony by Carl B. Feldbaum,
president, Biotechnology Industry Organization (BIO), to Robert L. Van
Nostrand, vice president and Chief Financial Officer of OSI Pharmaceuticals.
"The major events of 2000 -- Pfizer granting OSI full development and
marketing rights to Tarceva(TM), our lead anti-cancer drug candidate, and two
successful financings raising a total of $487 million -- transformed the
status and future prospects of the Company," stated Mr. Van Nostrand. "It is
an honor to be recognized by the biotech industry for our accomplishments."
The Helix Award is jointly sponsored by the State University of New York
at Stony Brook, the Center for Biotechnology and presented in conjunction with
BIO. It is awarded on behalf of the Long Island Biotech community. "The Long
Island biotech community is proud to promote the highest standards of
achievement among biotech companies," said Clinton T. Rubin, director, Center
for Biotechnology.
The Helix Award is open to public and private U.S. or foreign-based
biotechnology companies. An independent panel of judges representing the
biotechnology community reviewed the submissions and KPMG LLP tabulated the
results.
Background on OSI Pharmaceuticals, Inc.
OSI Pharmaceuticals is a leading biopharmaceutical company with a
substantial portfolio of product opportunities for commercialization with the
pharmaceutical industry. OSI utilizes a comprehensive drug discovery and
development capability to facilitate the rapid and cost-effective discovery
and development of novel, small molecule compounds against more than 40 gene
targets. http://www.osip.com
Background on sponsors
BIO represents more than 950 biotechnology companies, academic
institutions, state biotechnology centers and related organizations in all 50
U.S. states and 33 other nations. BIO members are involved in the research
and development of health-care, agricultural, industrial and environmental
biotechnology products. http://www.bio.org
The Center for Biotechnology is a New York State Center for Advanced
Technology in Medical Biotechnology. The Center for Biotechnology was
established in 1983 as a cooperative research and development partnership
between universities, private industry, and New York State. Its goal has been
to capitalize on the resources of New York's medical biotechnology research
for the purpose of fueling economic development in New York State.
http://www.biotech.sunysb.edu
SUNY Stony Brook has assumed an important role in the development of Long
Island's biotechnology industry through its Center for Advanced Technology in
Medical Biotechnology and the Long Island High Technology Incubator program.
Collectively, they have supported the establishment of more than 70 high
technology companies. Eight biosciences companies have "graduated" from this
program. Five are publicly traded with annual revenues in excess of $110
million. Additional information on the University can be accessed at
http://www.sunysb.edu .
SOURCE Biotechnology Industry Organization
 back to top
Related links:
http://www.bio.org
http://www.biotech.sunysb.edu http://www.sunysb.edu
http://www.osip.com
CONTACT:
Rich Catalano of OSI Pharmaceuticals, Inc.,
631-425-6000; or Peper Long of the Biotechnology Industry
Organization, 619-525-6241
|
